Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Insmed, with a price target of $111.26. The company’s shares closed yesterday at $111.26. Take advantage ...

Cannabinoids are specific chemical compounds found in cannabis, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Research is increasingly su ...

The second half of 2025 could be much more favorable for stockpickers looking for the best small-cap stocks to buy.That might ...